Some innovative drugs (antibody drug conjugates, CDK4/6 inhibitors, PARP inhibitors, selective estrogen degraders, and immune checkpoint inhibitors) have allowed for considerable improvements in outcomes for patients with breast cancer of all subtypes. This evidence concerns the gene CDK4 and breast cancer.